SHANGHAI FUSTAR PHARMACEUTICALS (GROUP) CO., LTD. (“FUSTAR PHARMACEUTICALS”) WILL HOLD ITS FIRST CLASS H SHAREHOLDER MEETING ON JUNE 26, 2024 AT THE SHANGHAI TIANHUI JIAFU PUTIK HOTEL, NO. 358 HONGXU ROAD, SHANGHAI, CHINA. The meeting will be held after the end of the Annual General Meeting and the Class A Shareholders' Meeting. The main agenda includes consideration of the adoption of general mandates for the repurchase of H shares and A shares, as well as amendments to the Articles of Association. The purpose of the share repurchase is to preserve the company's value and shareholders' interests and will be carried out in accordance with the relevant laws and regulations of China and Hong Kong. The number of H shares and A shares...Show More

SHANGHAI FUSTAR PHARMACEUTICALS (GROUP) CO., LTD. (“FUSTAR PHARMACEUTICALS”) WILL HOLD ITS FIRST CLASS H SHAREHOLDER MEETING ON JUNE 26, 2024 AT THE SHANGHAI TIANHUI JIAFU PUTIK HOTEL, NO. 358 HONGXU ROAD, SHANGHAI, CHINA. The meeting will be held after the end of the Annual General Meeting and the Class A Shareholders' Meeting. The main agenda includes consideration of the adoption of general mandates for the repurchase of H shares and A shares, as well as amendments to the Articles of Association. The purpose of the share repurchase is to preserve the company's value and shareholders' interests and will be carried out in accordance with the relevant laws and regulations of China and Hong Kong. The number of H shares and A shares repurchased shall not exceed 10% of the total issued and shall be subject to the approval of a special resolution of the General Meeting. The Executive Directors of Fuxing Pharmaceuticals include Mr. Wu Yifang, Mr. Wang Ke Chin, Ms. Guan Xiaofui and Mr. Wen De Yung. The Non-Executive Directors are Mr. Chan Qiyu, Mr. Yao Fang, Mr. Xu Xiaoliang and Mr. Pan Tung Fai. The Independent Non-Executive Directors are Ms. Li Ling, Mr. Tu Tung Leung, Mr. Wang Yuanchi and Mr. Yu Zi Shan.